Quanzhou executed the coronary drug coating balloon with the amount of procurement results

Source: Quanzhou Network

It can save patients more than 12 million yuan per year

According to the report of Quanzhou Network on January 19, in order to continue to promote the centralized procurement of high-value medical consumables, realize the comprehensive price reduction of high-value consumables for coronary interventional surgery, and effectively reduce the medical burden of the people, Quanzhou officially implemented the results of the procurement of coronary drug coating balloons in the Interprovincial Alliance yesterday. The reporter learned from the Quanzhou Municipal Medical Insurance Bureau that the average price of the selected products has dropped by 70%, and it is expected to save more than 12 million yuan for patients every year.

7 selected products with an average price reduction of 70%

According to reports, the interprovincial alliance coronary drug coating balloon with volume procurement finally had 7 products selected by 6 enterprises of CardionOVUM GmbH of Kaideno Co., Ltd., Shanghai Yingsheng Medical Technology Co., Ltd., Liaoning Yanyi Biotechnology Co., Ltd., Lepu (Beijing) Medical Device Co., Ltd., B. Braun Melsungen AG, Shanghai Shenqi Medical Technology Co., Ltd., with a selection rate of 88%, and the average price of the selected products was about 6300 yuan. Previously, the average price of such products was about 15,000 yuan, and the average price fell by 70% and the maximum decrease was 77%. The selected products have complete specifications and models, both imported products and domestic products, especially all mainstream products currently used in clinical use are all selected, which can effectively meet the needs of the clinical frontline and effectively achieve quality and price reduction.

The results of the selection were hung on the Fujian Pharmaceutical equipment joint sunshine procurement platform on January 14, and officially implemented on January 18. Quanzhou second-level and above public medical institutions and military medical institutions stationed in Quanzhou participated.

Inclusion in medicament payment at the selected price

Coronary drug-coated balloons are centrally purchased with the amount of selected products to be included in the scope of medical insurance payment at the selected price, and there is no personal out-of-pocket payment ratio, which is paid according to the provisions of basic medical insurance.

For non-selected coronary drug-coated balloons, the maximum payment limit of medical insurance is set at 10,000 yuan, and individuals within 10,000 yuan pay 20% out of pocket before being included in the scope of medical insurance payment, paid according to the provisions of basic medical insurance, and the part exceeding 10,000 yuan is paid by the patient.

Centralized procurement work always adheres to "zero tolerance" for quality problems, and ensures the quality and safety of selected products with strict rules and system design. The drug regulatory department will also include all selected products in the regulatory focus, strengthen supervision and inspection and product sampling, strengthen the quality supervision of the whole life cycle of production, circulation and use, consolidate the main responsibility of enterprises, strictly abide by the bottom line of quality and safety, and ensure that price reduction does not degrade quality.

【News Extension】

The national collection of coronary stents landed in Quanzhou for one year

Since January 1, 2021, Quanzhou has officially implemented the selected varieties determined by the centralized procurement of coronary stents organized by the state. The coronary stents purchased in a centralized manner involve 10 varieties produced by 8 Chinese and foreign enterprises such as Yisheng Technology, Shanghai Minimally Invasive Medical, and Lepu Medical, with a selected price of 469 yuan to 798 yuan. The average price of the selected coronary stent products dropped from about 13,000 yuan to about 700 yuan, compared with 2019, the average price of the same products of the same enterprises was reduced by 93%, of which the average price of domestic products was reduced by 92%, and the average price of imported products was reduced by 95%, which significantly reduced the burden of medical expenses for the masses, and Quanzhou could save 20 million yuan in medical expenses for patients every year. (Reporter Xu Yimei Correspondent Wang Yueqing Xiao Jingwei text/photo)